Transition from intravenous treprostinil to enteral selexipag in an infant with pulmonary arterial hypertension.
Cardiol Young
; 29(6): 849-851, 2019 Jun.
Article
em En
| MEDLINE
| ID: mdl-31379316
ABSTRACT
Selexipag is an enteral, selective prostacyclin IP receptor agonist approved for pulmonary hypertension in adults. There are few reports of its use in children and none in infants. We report the first transition of an infant (11.5 months, 8.6 kg) from intravenous treprostinil (40 ng/kg/minute) to enteral selexipag (400 mcg twice daily) with a good response and no adverse effects.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Pirazinas
/
Pressão Propulsora Pulmonar
/
Epoprostenol
/
Hipertensão Arterial Pulmonar
/
Acetamidas
Tipo de estudo:
Diagnostic_studies
Limite:
Humans
/
Male
/
Newborn
Idioma:
En
Revista:
Cardiol Young
Assunto da revista:
ANGIOLOGIA
/
CARDIOLOGIA
/
PEDIATRIA
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
Estados Unidos